-
Category
Proteins & Peptides
-
Long description
This peptide is the immunogen used to make Cat # X2761P. _x000B__x000B_Protects against mitochondrial dysfunction during cellular stress, potentially by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy). It is necessary for PARK2 recruitment to dysfunctional mitochondria to initiate their degradation. Defects in PINK1 are the cause of Parkinson disease type 6 (PARK6). A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep.
-
Antibody come from
Hybridoma produced by the fusion of splenocytes from mice immunized with isolated M13 phage coat proteins and mouse myeloma cells.
-
Other description
Provided as solution in phosphate buffered saline with 0.08% sodium azide.
-
Clone
not specified
-
Antigen antibody binding interaction
PINK1 (G309D Mutant) - Blocking Peptide
-
Antibody is raised in
see techfile
-
Antibody s reacts with
Blocking Peptide to Cat # X2761P
-
Antibody s reacts with these species
This antibody doesn't cross react with other species
-
Antibody s specificity
No Data Available
-
Application
Blocking Peptide
-
Antibody s suited for
Antibody specific for the gp3 protein. Antibody can be used for immunohistochemistry, Western blot (1-5 µg/ml), Flow cytometry (1 µg/106 cells) and ELISA. Optimal concentration should be evaluated by serial dilutions.
-
Storage
-20ºC
-
Relevant references
1- Van Wezenbeek P.M., Schoenmakers J.G.; Nucleotide sequence of the genes III, VI and I of bacteriophage M13; Nucleic Acids Res. 6:2799-2818(1979)._x000B_2- Van Wezenbeek P.M., Hulsebos T.J., Schoenmakers J.G.; Nucleotide sequence of the filamentous bacteriophage M13 genome: comparison with phage fd; Gene 11:129-148(1980)._x000B_3- Cleary J.M., Ray D.S.; Deletion analysis of the cloned replication origin region from bacteriophage M13; J. Virol. 40:197-203(1981)._x000B_4- Hines J.C., Ray D.S.; Construction and characterization of new coliphage M13 cloning vectors; Gene 11:207-218(1980)._x000B_5- Yanisch-Perron C., Vieira J., Messing J.; Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors; Gene 33:103-119(1985)._x000B_6- Messing J.; New M13 Vectors for Cloning; Meth. Enzymol. 101:20 78(1983)._x000B_7- Sanger F., Nicklen S., Coulson A.R.; DNA sequencing with chain-terminating inhibitors; Proc. Natl. Acad. Sci. U.S.A. 74:5463-5468(1977)._x000B_8- Zoller M.J., Smith M.; Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors; Meth. Enzymol. 100:468-500(1983)._x000B_9- Hu N.T., Messing J.; The making of strand-specific M13 probes; Gene 17:271-277(1982)._x000B_10- Heidecker G., Messing J., Gronenborn B.; A versatile primer for DNA sequencing in the M13mp2 cloning system; Gene 10:69-73(1980)._x000B_11- Ebright R., Dong Q., Messing J.; Corrected nucleotide sequence of M13mp18 gene III; Gene 114:81-83(1992)._x000B_12- Hong G.F.; A method for sequencing single-stranded cloned DNA in both directions; Biosci. Rep. 1:243-252(1981)._x000B_13- Messing J.; Multipurpose cloning system based on the single-stranded DNA bacteriophage M13; Recombinant DNA Technical Bulletin NIH 2:43-48(1979).
-
Protein number
see ncbi
-
Warnings
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
-
-
Test
You can block the antibody by the specific target amino acid sequence of peptide.
-
Properties
blocking peptide
-
Description
Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.
